Melanoma-associated antigen 3 (MAGE3 or MAGEA3), a protein belonging to the melanoma-associated antigen gene family, has been found in many tumors, including melanoma, non-small cell lung cancer, hematological malignancies, and others. MAGE genes are activated in tumors of many different histological types. Due to this strict tumor specificity, MAGE antigens are of particular interest in cancer immunotherapy. The major histocompatibility complex (MHC) is a large locus on vertebrate DNA that contains a tightly linked set of polymorphic genes that encode cell surface proteins critical to the adaptive immune system. Classical MHC molecules present epitopes to the TCR of CD8+ T lymphocytes. The antigens/ligands of many of these molecules are still unknown, but they can interact with CD8+ T cells, NKT cells and NK cells. Current TCR therapies use MHC class I-restricted TCRs to genetically engineer CD8+ T cells or large numbers of T cells for patient treatment. This product is designed as a tool for the delivery and expression of fusion MAGE3-MHC mRNA for vaccine research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of MAGE3/MHC mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The GenPept accession number for MAGE3 is NP_005353 and the GenPept accession number for MHC is NP_002108. The full-length amino acid sequence of this MAGE3-MHC mRNA-LNP product is available upon request.